echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Priority purchase and use of selected products!

    Priority purchase and use of selected products!

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, July 27, July 23, the Shanghai Municipal Drug Administration, Medical Insurance Bureau, and Health Commission jointly issued the Work Notice (Shanghai Medical Insurance Price Caifa [2021] No.
    20)” (hereinafter referred to as the “Notice”), in accordance with the principles of quantity procurement, quantity and price linkage, and promotion of market competition, continue to promote the centralized procurement and use of high-value medical consumables
    .
     
    One is to give priority to purchasing and using selected products
     
    The "Notice" stipulates that all medical insurance designated medical institutions and non-profit medical institutions in Shanghai (collectively referred to as "medical institutions") shall not influence the selection of selected products on the grounds of total cost control, "consumption ratio", and the number of basic consumption items in hospitals.
    Procurement and reasonable use
    .
     
    Medical institutions shall purchase selected products from the operating (or distribution) enterprises designated by the selected enterprises through the "Shanghai Pharmaceutical Purchasing Service and Regulatory Information System" (referred to as "Sunshine Purchasing Platform") , and implement zero-markup sales in accordance with regulations.
    Any form is strictly prohibited.
    The “second bargaining” behavior of the selected product, and the purchase usage volume should not be less than the negotiated purchase volume of the selected product .
    After the agreed procurement volume is completed, medical institutions are encouraged to continue to give priority to using the selected products .


     
    Except for the selected products, other similar products shall be regarded as record products
    .
    In principle, the online purchase of registered products on the Sunshine Purchasing Platform is suspended
    .
    Medical institutions may, based on their clinical needs, on the premise of prioritizing the purchase of selected products, submit a record purchase to the Shanghai Municipal Pharmaceutical Centralized Bidding and Purchasing Management Office (the "Municipal Pharmaceutical Office"), and the purchase price is determined through independent bargaining
    .
    Medical institutions shall establish strict approval procedures for purchasing and using registered products
    .
     
      The second is to ensure timely payment and product supply
     
      The "Notice" emphasizes that medical institutions, as the first person responsible for the settlement of high-value medical consumables, should pay the terminal supplier in a timely manner.
    In principle, the payment time should not exceed the end of the next month after the delivery acceptance is passed, reducing the supplier's transaction Cost
    .
     
      Medical institutions shall promptly sign a tripartite purchase and sale agreement with the selected enterprise and its designated operating (or distribution) enterprise to clarify the rights and responsibilities of each party
    .
     
      The selected enterprises shall ensure that they are supplied in sufficient quantities at the selected price during the procurement cycle.
    Except for national policy adjustments or force majeure, they shall not stop supply for any reason
    .
    The operating (or distribution) enterprise designated by the selected enterprise shall supply the selected products for centralized procurement to medical institutions through the Sunshine Procurement Platform and issue invoices separately
    .
     
      picture
     
      The third is to explore the implementation of medical insurance payment standards
     
      In terms of medical insurance payment, the "Notice" mentioned the expenses incurred by Shanghai insured persons using the selected coronary balloon dilatation catheters or coronary balloon drug-coated catheters, and canceled the original proportionate self-pay part, and fully included in the medical insurance payment scope , Pay directly according to the basic medical insurance regulations
    .
     
      For the insured persons in this city who use unselected products, Shanghai will cancel the original proportionate classification of self-conceit.
    The maximum medical insurance payment standard for coronary balloon dilatation catheters is 1,410 yuan, and the maximum medical insurance payment standard for coronary balloon drug-coated catheters It is 16,080 yuan, and it will be adjusted dynamically according to the market competition pattern and the income and expenditure of the medical insurance fund
    .
     
      If the unit price of similar products is lower than (including) the highest medical insurance payment standard, the full amount shall be included in the medical insurance payment scope and paid directly according to the basic medical insurance regulations of this city
    .
     
      If the unit price of similar products is higher than the highest medical insurance payment standard, the excess part will be paid by the insured person (except for the old Red Army, retired personnel and revolutionary disabled soldiers of grade 1 to 6), and will not be included in the various burden reduction scopes of the basic medical insurance for employees, nor will it be included The coverage of serious illness insurance for urban and rural residents
    .
     
      The fourth is to strengthen departmental coordination
     
      The "Notice" proposed that the Shanghai medical insurance administrative department should include the procurement and use of selected products by medical institutions in the scope of medical insurance management assessment
    .
    In order to encourage medical institutions to use selected products and actively control the cost of high-value medical consumables, the medical insurance costs saved by the use of selected products in medical institutions will not be adjusted or reduced on the basis of prepayment of medical insurance costs
    .
    On the premise of ensuring that the patient's conceited part fully enjoys the price reduction effect of centralized procurement, the corresponding (DRG/DIP) medical insurance payment standard may not be lowered in the first year, and will be adjusted regularly in accordance with the rules
    .
     
      The Shanghai Pharmaceutical Affairs Office is the city's centralized procurement agency for high-value medical consumables, responsible for publishing the selected products and filing product information
    .
    Strengthen the analysis of the procurement situation of the selected products in the centralized procurement of medical institutions, control the procurement ratio of the selected products and the registered products through the sunshine procurement platform, and regularly announce the procurement of the registered products to the medical institutions
    .
    The untrustworthy behaviors of relevant medical consumables production and operation enterprises in fulfilling agreements, etc.
    shall be dealt with in accordance with the relevant provisions of this Municipality’s medical prices and the credit evaluation system for recruitment and procurement
    .
     
      The Shanghai Municipal Health Administration is responsible for monitoring the use of medical consumables in medical institutions, and punishes medical institutions that do not purchase and use selected products in accordance with regulations in the performance evaluation of public hospitals and the target responsibility assessment of medical institution leaders
    .
    Standardize the medical service behavior of clinicians, guarantee patients' informed consent, strictly control unreasonable use, improve the supervision and management mechanism, and strictly investigate and punish violations of the clinical use of high-value medical consumables
    .
     
      The district health administrative departments are responsible for urging the medical institutions in their jurisdictions to settle timely settlements with enterprises in accordance with regulations, strictly investigate the problem of non-time settlement of payment, and cooperate with the district medical insurance departments to do a good job of publicity and explanation
    .
     
      The drug regulatory authorities at all levels in Shanghai are responsible for strengthening the supervision of the selected products, and intensifying random inspections and unannounced inspections
    .
    Once serious quality problems are found in the products selected in the centralized procurement, the procurement qualification will be terminated in accordance with the procedures
    .
      Medical Network, July 27, July 23, the Shanghai Municipal Drug Administration, Medical Insurance Bureau, and Health Commission jointly issued the Work Notice (Shanghai Medical Insurance Price Caifa [2021] No.
    20)” (hereinafter referred to as the “Notice”), in accordance with the principles of quantity procurement, quantity and price linkage, and promotion of market competition, continue to promote the centralized procurement and use of high-value medical consumables
    .
     
      One is to give priority to purchasing and using selected products
     
      The "Notice" stipulates that all medical insurance designated medical institutions and non-profit medical institutions in Shanghai (collectively referred to as "medical institutions") shall not influence the selection of selected products on the grounds of total cost control, "consumption ratio", and the number of basic consumption items in hospitals.
    Procurement and reasonable use
    .
     
      Medical institutions shall purchase selected products from the operating (or distribution) enterprises designated by the selected enterprises through the "Shanghai Pharmaceutical Purchasing Service and Regulatory Information System" (referred to as "Sunshine Purchasing Platform") , and implement zero-markup sales in accordance with regulations.
    Any form is strictly prohibited.
    The “second bargaining” behavior of the selected product, and the purchase usage volume should not be less than the negotiated purchase volume of the selected product .
    After the agreed procurement volume is completed, medical institutions are encouraged to continue to give priority to using the selected products .


     
      Except for the selected products, other similar products shall be regarded as record products
    .
    In principle, the online purchase of registered products on the Sunshine Purchasing Platform is suspended
    .
    Medical institutions may, based on their clinical needs, on the premise of prioritizing the purchase of selected products, submit a record purchase to the Shanghai Municipal Pharmaceutical Centralized Bidding and Purchasing Management Office (the "Municipal Pharmaceutical Office"), and the purchase price is determined through independent bargaining
    .
    Medical institutions shall establish strict approval procedures for purchasing and using registered products
    .
     
      The second is to ensure timely payment and product supply
     
      The "Notice" emphasizes that medical institutions, as the first person responsible for the settlement of high-value medical consumables, should pay the terminal supplier in a timely manner.
    In principle, the payment time should not exceed the end of the next month after the delivery acceptance is passed, reducing the supplier's transaction Cost
    .
     
      Medical institutions shall promptly sign a tripartite purchase and sale agreement with the selected enterprise and its designated operating (or distribution) enterprise to clarify the rights and responsibilities of each party
    .
     
      The selected enterprises shall ensure that they are supplied in sufficient quantities at the selected price during the procurement cycle.
    Except for national policy adjustments or force majeure, they shall not stop supply for any reason
    .
    The operating (or distribution) enterprise designated by the selected enterprise shall supply the selected products for centralized procurement to medical institutions through the Sunshine Procurement Platform and issue invoices separately
    .
     
      picture
     
      The third is to explore the implementation of medical insurance payment standards
     
      In terms of medical insurance payment, the "Notice" mentioned the expenses incurred by Shanghai insured persons using the selected coronary balloon dilatation catheters or coronary balloon drug-coated catheters, and canceled the original proportionate self-pay part, and fully included in the medical insurance payment scope , Pay directly according to the basic medical insurance regulations
    .
     
      For the insured persons in this city who use unselected products, Shanghai will cancel the original proportionate classification of self-conceit.
    The maximum medical insurance payment standard for coronary balloon dilatation catheters is 1,410 yuan, and the maximum medical insurance payment standard for coronary balloon drug-coated catheters It is 16,080 yuan, and it will be adjusted dynamically according to the market competition pattern and the income and expenditure of the medical insurance fund
    .
     
      If the unit price of similar products is lower than (including) the highest medical insurance payment standard, the full amount shall be included in the medical insurance payment scope and paid directly according to the basic medical insurance regulations of this city
    .
     
      If the unit price of similar products is higher than the highest medical insurance payment standard, the excess part will be paid by the insured person (except for the old Red Army, retired personnel and revolutionary disabled soldiers of grade 1 to 6), and will not be included in the various burden reduction scopes of the basic medical insurance for employees, nor will it be included The coverage of serious illness insurance for urban and rural residents
    .
     
      The fourth is to strengthen departmental coordination
     
      The "Notice" proposed that the Shanghai medical insurance administrative department should include the procurement and use of selected products by medical institutions in the scope of medical insurance management assessment
    .
    In order to encourage medical institutions to use selected products and actively control the cost of high-value medical consumables, the medical insurance costs saved by the use of selected products in medical institutions will not be adjusted or reduced on the basis of prepayment of medical insurance costs
    .
    On the premise of ensuring that the patient's conceited part fully enjoys the price reduction effect of centralized procurement, the corresponding (DRG/DIP) medical insurance payment standard may not be lowered in the first year, and will be adjusted regularly in accordance with the rules
    .
     
      The Shanghai Pharmaceutical Affairs Office is the city's centralized procurement agency for high-value medical consumables, responsible for publishing the selected products and filing product information
    .
    Strengthen the analysis of the procurement situation of the selected products in the centralized procurement of medical institutions, control the procurement ratio of the selected products and the registered products through the sunshine procurement platform, and regularly announce the procurement of the registered products to the medical institutions
    .
    The untrustworthy behaviors of relevant medical consumables production and operation enterprises in fulfilling agreements, etc.
    shall be dealt with in accordance with the relevant provisions of this Municipality’s medical prices and the credit evaluation system for recruitment and procurement
    .
     
      The Shanghai Municipal Health Administration is responsible for monitoring the use of medical consumables in medical institutions, and punishes medical institutions that do not purchase and use selected products in accordance with regulations in the performance evaluation of public hospitals and the target responsibility assessment of medical institution leaders
    .
    Standardize the medical service behavior of clinicians, guarantee patients' informed consent, strictly control unreasonable use, improve the supervision and management mechanism, and strictly investigate and punish violations of the clinical use of high-value medical consumables
    .
     
      The district health administrative departments are responsible for urging the medical institutions in their jurisdictions to settle timely settlements with enterprises in accordance with regulations, strictly investigate the problem of non-time settlement of payment, and cooperate with the district medical insurance departments to do a good job of publicity and explanation
    .
     
      The drug regulatory authorities at all levels in Shanghai are responsible for strengthening the supervision of the selected products, and intensifying random inspections and unannounced inspections
    .
    Once serious quality problems are found in the products selected in the centralized procurement, the procurement qualification will be terminated in accordance with the procedures
    .
      Medical Network, July 27, July 23, the Shanghai Municipal Drug Administration, Medical Insurance Bureau, and Health Commission jointly issued the Work Notice (Shanghai Medical Insurance Price Caifa [2021] No.
    20)” (hereinafter referred to as the “Notice”), in accordance with the principles of quantity procurement, quantity and price linkage, and promotion of market competition, continue to promote the centralized procurement and use of high-value medical consumables
    .
     
      One is to give priority to purchasing and using selected products
      One is to give priority to purchasing and using selected products
     
      The "Notice" stipulates that all medical insurance designated medical institutions and non-profit medical institutions in Shanghai (collectively referred to as "medical institutions") shall not influence the selection of selected products on the grounds of total cost control, "consumption ratio", and the number of basic consumption items in hospitals.
    Procurement and reasonable use
    .
     
      Medical institutions shall purchase selected products from the operating (or distribution) enterprises designated by the selected enterprises through the "Shanghai Pharmaceutical Purchasing Service and Regulatory Information System" (referred to as "Sunshine Purchasing Platform") , and implement zero-markup sales in accordance with regulations.
    Any form is strictly prohibited.
    The “second bargaining” behavior of the selected product, and the purchase usage volume should not be less than the negotiated purchase volume of the selected product .
    After the agreed procurement volume is completed, medical institutions are encouraged to continue to give priority to using the selected products .


    Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise Enterprise
     
      Except for the selected products, other similar products shall be regarded as record products
    .
    In principle, the online purchase of registered products on the Sunshine Purchasing Platform is suspended
    .
    Medical institutions may, based on their clinical needs, on the premise of prioritizing the purchase of selected products, submit a record purchase to the Shanghai Municipal Pharmaceutical Centralized Bidding and Purchasing Management Office (the "Municipal Pharmaceutical Office"), and the purchase price is determined through independent bargaining
    .
    Medical institutions shall establish strict approval procedures for purchasing and using registered products
    .
    Tender Tender Tender
     
      The second is to ensure timely payment and product supply
      The second is to ensure timely payment and product supply
     
      The "Notice" emphasizes that medical institutions, as the first person responsible for the settlement of high-value medical consumables, should pay the terminal supplier in a timely manner.
    In principle, the payment time should not exceed the end of the next month after the delivery acceptance is passed, reducing the supplier's transaction Cost
    .
     
      Medical institutions shall promptly sign a tripartite purchase and sale agreement with the selected enterprise and its designated operating (or distribution) enterprise to clarify the rights and responsibilities of each party
    .
     
      The selected enterprises shall ensure that they are supplied in sufficient quantities at the selected price during the procurement cycle.
    Except for national policy adjustments or force majeure, they shall not stop supply for any reason
    .
    The operating (or distribution) enterprise designated by the selected enterprise shall supply the selected products for centralized procurement to medical institutions through the Sunshine Procurement Platform and issue invoices separately
    .
     
      picture
      picture
     
      The third is to explore the implementation of medical insurance payment standards
      The third is to explore the implementation of medical insurance payment standards
     
      In terms of medical insurance payment, the "Notice" mentioned the expenses incurred by Shanghai insured persons using the selected coronary balloon dilatation catheters or coronary balloon drug-coated catheters, and canceled the original proportionate self-pay part, and fully included in the medical insurance payment scope , Pay directly according to the basic medical insurance regulations
    .
     
      For the insured persons in this city who use unselected products, Shanghai will cancel the original proportionate classification of self-conceit.
    The maximum medical insurance payment standard for coronary balloon dilatation catheters is 1,410 yuan, and the maximum medical insurance payment standard for coronary balloon drug-coated catheters It is 16,080 yuan, and it will be adjusted dynamically according to the market competition pattern and the income and expenditure of the medical insurance fund
    .
     
      If the unit price of similar products is lower than (including) the highest medical insurance payment standard, the full amount shall be included in the medical insurance payment scope and paid directly according to the basic medical insurance regulations of this city
    .
     
      If the unit price of similar products is higher than the highest medical insurance payment standard, the excess part will be paid by the insured person (except for the old Red Army, retired personnel and revolutionary disabled soldiers of grade 1 to 6), and will not be included in the various burden reduction scopes of the basic medical insurance for employees, nor will it be included The coverage of serious illness insurance for urban and rural residents
    .
     
      The fourth is to strengthen departmental coordination
      The fourth is to strengthen departmental coordination
     
      The "Notice" proposed that the Shanghai medical insurance administrative department should include the procurement and use of selected products by medical institutions in the scope of medical insurance management assessment
    .
    In order to encourage medical institutions to use selected products and actively control the cost of high-value medical consumables, the medical insurance costs saved by the use of selected products in medical institutions will not be adjusted or reduced on the basis of prepayment of medical insurance costs
    .
    On the premise of ensuring that the patient's conceited part fully enjoys the price reduction effect of centralized procurement, the corresponding (DRG/DIP) medical insurance payment standard may not be lowered in the first year, and will be adjusted regularly in accordance with the rules
    .
     
      The Shanghai Pharmaceutical Affairs Office is the city's centralized procurement agency for high-value medical consumables, responsible for publishing the selected products and filing product information
    .
    Strengthen the analysis of the procurement situation of the selected products in the centralized procurement of medical institutions, control the procurement ratio of the selected products and the registered products through the sunshine procurement platform, and regularly announce the procurement of the registered products to the medical institutions
    .
    The untrustworthy behaviors of relevant medical consumables production and operation enterprises in fulfilling agreements, etc.
    shall be dealt with in accordance with the relevant provisions of this Municipality’s medical prices and the credit evaluation system for recruitment and procurement
    .
     
      The Shanghai Municipal Health Administration is responsible for monitoring the use of medical consumables in medical institutions, and punishes medical institutions that do not purchase and use selected products in accordance with regulations in the performance evaluation of public hospitals and the target responsibility assessment of medical institution leaders
    .
    Standardize the medical service behavior of clinicians, guarantee patients' informed consent, strictly control unreasonable use, improve the supervision and management mechanism, and strictly investigate and punish violations of the clinical use of high-value medical consumables
    .
    Hospital hospital hospital
     
      The district health administrative departments are responsible for urging the medical institutions in their jurisdictions to settle timely settlements with enterprises in accordance with regulations, strictly investigate the problem of non-time settlement of payment, and cooperate with the district medical insurance departments to do a good job of publicity and explanation
    .
     
      The drug regulatory authorities at all levels in Shanghai are responsible for strengthening the supervision of the selected products, and intensifying random inspections and unannounced inspections
    .
    Once serious quality problems are found in the products selected in the centralized procurement, the procurement qualification will be terminated in accordance with the procedures
    .
    Medicine, medicine, medicine
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.